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The chemical examination of the ethanolic extract of manglicolous lichen Parmotrema tinctorum (Pt-Et) has resulted in 
isolation of six known metabolites, i.e., methyl-β-orcinolcarboxylate (1), isolecanoric acid (2), methyl-2,6-dihydroxy-4-
methylbenzoate (3), haematommic acid (4), ethyl haematommate (5), and atranorin (6). All the isolates 1-6 and Pt-Et have 
been screened against DPPH and superoxide free radicals, six different cancer cell lines (MDA-MB-231, SW620, HeLa, 
FADU, A549, SKOV3) and one normal human cell line (NHME). Compound 3 exhibits prominent inhibition of superoxide 
free radical, which appears to be better than that of the standard (ascorbic acid) with an IC50 value of 26.0 µg/mL. From the 
SRB assay results, it is observed that the better IC50 values have been obtained from 4 and 5 on HeLa, FADU, and A549, 
respectively. In addition, all the tested samples show low cell lysis on NHME, which indicates low toxicity. Consequently, 
the outcomes revealed that P. tinctorum could be a new source to treat oxidative stress and cancer. This work is the first 
report of antioxidant and cytotoxicity studies on the isolated metabolites 1-6. 
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A symbiotic organism known as the lichen belongs to 
the group of epiphytes, which have an aptitude to 
persist on any substratum or geographical region1,2. 
Manglicolous lichens are one of the types of lichen, 
which, mainly, survived on the mangroves2,3. 
Throughout ages, lichens are used for the treatment of 
several diseases due to their unique survival and their 
bioactive secondary metabolites. Lichens with their 
secondary metabolites exert a diverse range of 
pharmacological actions that include analgesic, 
antibiotic, anti-inflammatory, antimycotic, antipyretic, 
antiviral, and cytotoxic effects3,4. Chiefly, manglicolous 
lichens display differences in their biological 
constituents and actions than normal lichens do. It is 
due to the fact of their physiological adaptation at the 
intertidal zone (environment in which having both the 
marine and freshwater)5. This led the researchers to 
gain interest in the biological screening of particular 
manglicolous lichens. There are very few 
pharmacological evaluation reports that exist, to date, 
on the manglicolous lichens2,4. 
As per the general studies, Parmotrema tinctorum 
(Despr. ex Nyl.) Hale belongs to family Parmeliaceae, 
which is the most prominent family of foliose lichen. 
Pharmacologically, the crude extracts of P. tinctorum 
possess antioxidant, antiglycation, α-amylase, α-
glucosidase, aldose reductase, tyrosinase, and 
carbohydrate digestive enzymes inhibitory activities3,6. 
Earlier the experiment which we had performed has 
established the phytochemical analysis along with 
total flavonoid and phenolic contents, antimicrobial, 
antioxidant and hypoglycaemic and, antihyperglycemic 
activities of this mangrove associated lichen  
P. tinctorum
3. In addition, we reported the chemical 
examination of ethyl acetate extract from P. tinctorum, 
which yielded two known metabolites – atranorin and 
ethyl everninate3. In continuation of our research on 
chemical and pharmacological evaluation of some 
Indian mangrove lichens and also based on  
the aforementioned properties of P. tinctorum, we 
examined by recollecting the P. tinctorum specimens 
(in October 2018) for its chemical and pharmacological 
properties which are reported on this research paper. 
 
Material and Methods 
 
Collection 
The specimens of mangrove associated lichen 
Parmotrema tinctorum (Despr. ex Nyl.) Hale was 
collected on the twigs of mangrove plant Excoecaria 
agallocha from Bhitharkanika Island, Rajnagar, 




Orissa, India (20°74’N and 86°87’E with 0 m 
elevation) on 18 October 2018. The P. tinctorum was 
authenticated by Dr. D. K. Upreti, CSIR-National 
Botanical Research Institute (NBRI), Lucknow with 
accession number 15-027176 had been deposited at 
Lichen herbarium, CSIR-NBRI, Lucknow, India. 
 
Chemicals 
All the chemicals used in the present experiment 
were of analytical grade. 1,1-diphenyl-2-picrylhydrazyl 
(DPPH), ascorbic acid, Sulforhodamine B (SRB) was 
from Sigma Aldrich (Mumbai, India); doxorubicin 
from the Avantis Pharma Ltd (Mumbai, India). 
 
Extraction of manglicolous lichen material 
The lichen specimens were carefully handpicked 
from the twigs of respective mangrove plants  
and allowed to shade dry. The dried lichen then  
(of about 10 g) were powdered, suspended in ethanol 
for a week, and evaporated under reduced pressure  
to obtain an ethanolic extract from P. tinctorum  
(Pt-Et, 2.10 g, 21%w/w) as a dark blackish solid.  
The Pt-Et (1.5 g) was then subjected to column 
chromatography by the increasing polarity of hexane 
and ethyl acetate (as a solvent system, which affords 
five fractions). Fraction I (90 mg) obtained in 10% 
hexane in ethyl acetate yielded 1 as colorless crystals 
(40 mg), fraction II (150 mg) obtained in 20% hexane 
in ethyl acetate yielded 2 and 3 as a yellowish solid 
(50 mg) and as pale yellow crystals (75 mg), 
respectively, fraction III (60 mg) obtained in 30% 
hexane in ethyl acetate yielded 4 as pale yellow 
needles (35 mg), fraction IV (160 mg) obtained in 
40% hexane in ethyl acetate yielded 5 as a greenish 
solid (15 mg), and fraction V (150 mg) obtained in 
50% hexane in ethyl acetate yielded 6 as colorless 





The antioxidant activity was assessed by the 1,1-
diphenyl-2-picrylhydrazyl (DPPH) radical assay7,8 in 
a triplet. Initially, 100 µL of 100 µM of DPPH in 
ethanol was prepared and reacted with known 
concentrations, i.e., 50, 100, 150 and 200 µg/mL for 
extracts and 25, 50, 75 and 100 µg/mL for the isolated 
metabolites and standard (ascorbic acid) samples, 
incubated for 30 mins. The absorbance was noted at 
517 nm on the UV-Visible spectrometer (Electron  
420 series spectrophotometer). The percentage 
inhibition was calculated using the below formula. 
Simultaneously, the IC50 was calculated using a linear 
graph section between percentage inhibition and 
concentration of the tested sample.  
 
Superoxide radical scavenging assay  
In the radical method8,9, the superoxide radicals 
generated from non-enzymatic phenazine methosulfate/ 
Nicotinamide adenine dinucleotide (PMS/NADH) 
reduces nitro blue tetrazolium (NBT) to purple 
formazan. To 1 mL of reaction mixture contained  
20 mM phosphate buffer (pH 7.4), 73 µM NADH,  
50 µM NBT, 15 µM PMS added various concentrations, 
i.e., 50, 100, 150 and 200 µg/mL for extracts and 25, 
50, 75 and 100 µg/mL for isolates/ascorbic acid and 
incubated for 10 min at room temperature and the 
absorbance was noted at 562 nm against the blank. 
The experiment was triplicated, and the data were 




Figure 1 — Secondary metabolites 1-6 isolated from Parmotrema tinctorum 




Percentage inhibition (%) = (Ac – As)/Ac × 100 
 
where Ac is the absorbance of the control. 
 




Cancer Cell lines 
MDA-MB-231 (Breast), SW620 (Colon), HeLa 
(Cervical), FADU (Head and Neck), A549 (Lung), 
SKOV3 (Ovary) and Normal Human Mammary 
Epithelial (NHME) (were kindly provided by 
National Centre for Cell Science, Pune. The cancer 
cells were maintained in MEM media (containing 
10% fetal calf serum, 5% mixture of penicillin (100 
units), and streptomycin (100 µg/mL) in the presence 
of 5% carbon dioxide incubator having 90% humidity 
at 37˚C for 72 h.  
 
Cell growth medium 
All the cancer cell lines were maintained in 
minimal essential medium (MEM) (adjusted to 10% 
(v/v) FBS, 1.5 g/mL NaHCO3, 0.1 mM MEM non-
essential amino acids and 1 mM sodium pyruvate). 
Three days prior to performing the assay, the cells 
were washed with sterilized PBS and grown using 
MEM media (supplemented with 0.25% trypsin in 
versene-EDTA and 10% FBS) and mixed to obtain 
homogeneous suspension of cells. The suspension 
was taken in a sterilized polypropylene tube, and the 
cell concentration in each well was determined by 
hematocytochameter chamber under a microscope 
using a 0.4% trypan blue solution. The minimal seed 
density must be 1.9 × 104 cells per well.  
 
Sample Preparation 
All the crude extracts and standards were dissolved 
in DMSO to 100 mg/mL and 10 µg/mL, respectively. 
The doxorubicin and DMSO were used as a standard 
and control, respectively. 
 
SRB Colorimetric assay 
The Sulforhodamine B assay10,11 is based on the 
estimation of cellular protein content. The prepared 
samples were taken in 96-well tissue-culture plate and 
added 190 µL screened ideal cell suspension and 
mixed occasionally and incubate at 37˚C with 5% 
CO2 and 90% relative humidity for 3 h. Then add  
100 µL cold TCA to each well and incubate at 4˚C for 
1 h. After that, the plates were gently washed using 
water, dried using a blow dryer, and air-dried at room 
temperature. To each completely dried well, add  
100 µL of 0.057% SRB solution, kept aside for  
30 min and quickly rinse with 1% acetic acid. To the 
dried plate add 200 µL of 10 mM Tris base (pH 10.5) 
solution, shake for 5 min and measure the OD at  
510 nm. The blank contains only medium, while the 
control has only cancer cells with no test samples. 
The percentage of growth inhibition was calculated 
using the below formula. 
 
% Growth inhibition = 100 – [(S – B)/(C – B)] × 100 
 
Where S is mean OD value of sample 
 
B is mean OD value of blank 
 
C is mean OD value of control 
 
Results and Discussion 
 
Chemistry 
Methyl-β-orcinolcarboxylate, 1: Colorless crystals. 
Mol. Formula: C10H12O4. Yield: 40 mg. Rf: 0.4 
(Hexane:ethyl acetate, 1:4); m.p.144-145°C. UV 
(Ethanol) λmax (log ɛ) 267 nm; 
1H NMR (DMSO-d6, 
400 MHz): δ 2.25 (3H, s, 10-CH3), 2.37 (3H, s,  
9-CH3), 3.95 (3H, s, 8-OCH3), 6.01 (1H, s, 4-OH), 
6.19 (1H, s, 5-ArH), 9.61 (1H, s, 2-OH); 13C NMR 
(DMSO-d6, 400 MHz): δ 8.74 (C-9), 21.63 (C-10), 
52.99 (C-8), 108.36 (C-1), 110.39 (C-3), 111.18  
(C-5), 141.36 (C-6), 160.68 (C-2), 162.09 (C-4), 
172.19 (C-7); ESI-MS positive mode: m/z 197.00 
[M+H+]. Calcd for C10H12O4: m/z 196.07 (Figure 1). 
Anal. Found: C, 61.76; H, 6.14. Calcd for: C, 61.22; 
H, 6.17%. 
Isolecanoric acid, 2: Yellowish solid. C16H14O7. 
Yield: 50 mg. Rf: 0.6 (Hexane:Ethyl acetate, 3:7); 
m.p.367-368°C. UV (Ethanol) λmax (log ɛ) 211 nm; 
1H NMR (CDCl3, 400 MHz): δ 2.49 (3H, s, 16-CH3), 
2.51 (3H, s, 14-CH3), 4.01 (1H, s, 12-OH), 4.06 (1H, 
s, 4-OH), 4.48 (1H, s, 2-OH), 6.48 (1H, s, 3-ArH), 
6.56 (1H, s, 5-ArH), 6.95 (1H, s, 11-ArH), 6.99 (1H, 
s, 13-ArH), 9.48 (1H, s, 15-COOH); 13C NMR 
(CDCl3, 400 MHz): δ 21.92 (C-14/C-16), 103.34  
(C-3), 106.18 (C-1), 106.58 (C-13), 112.26 (C-5), 
115.18 (C-9), 118.01 (C-11), 142.78 (C-10), 144.92 
(C-6), 155.31 (C-8), 162.64 (C-12), 163.72 (C-4), 
164.75 (C-2), 168.00 (C-7), 171.86 (C-15); ESI-MS 
positive mode: m/z 319.9 [M+H+]. Calcd for 
C16H14O7: m/z 318.07 (Figure 1). Anal. Found: C, 
60.71; H, 4.72. Calcd for: C, 60.38; H, 4.43%. 
Methyl-2,6-dihydroxy-4-methylbenzoate, 3: Pale 
yellow crystals. Mol. Formula: C9H10O4. Yield:  




75 mg. Rf: 0.6 (Hexane:Ethyl acetate, 1:1); m.p.138-
139°C. UV (Ethanol) λmax (log ɛ) 219.5 nm; 
1H NMR 
(DMSO-d6, 400 MHz): δ 2.23 (3H, s, 9-CH3), 3.75 
(3H, s, 8-OCH3), 6.12 (2H, d, J= 1.2 Hz, 3,5-ArH), 
9.93 (1H, s, 6-OH), 10.65 (1H, s, 2-OH); 13C NMR 
(DMSO-d6, 400 MHz): δ 22.46 (C-9), 52.16 (C-8), 
100.83 (C-1), 107.93 (C-5), 110.58 (C-3), 141.15 (C-
4), 161.46 (C-6/C-2), 170.59 (C-7); ESI-MS negative 
mode: m/z 183.0 [M-H+]. Calcd for C9H10O4: m/z 
182.06 (Figure 1). Anal. Found: C, 59.66; H, 5.62. 
Calcd for: C, 59.34; H, 5.53%. 
Haematommic acid, 4: Pale yellow needles. Mol. 
Formula: C9H8O5. Yield: 35 mg. Rf: 0.4 (Hexane: 
Ethyl acetate, 1:1); m.p.172-173°C. UV (Ethanol) λmax 
(log ɛ) 219.5 nm; 1H NMR (DMSO-d6, 400 MHz): δ 
2.54 (3H, s, 9-CH3), 6.42 (1H, s, 5-ArH), 9.68 (1H, s, 
4-OH), 10.59 (1H, s, 2-OH), 11.46 (1H, s,  
7-COOH), 13.75 (1H, s, 8-CHO); 13C NMR (DMSO-
d6, 400 MHz): δ 17.10 (C-9), 105.25 (C-1), 109.34  
(C-3/C-5), 155.22 (C-6), 163.90 (C-4), 167.04 (C-2), 
173.42 (C-7), 191.73 (C-8); ESI-MS negative mode: 
m/z 198.30 [M-H+]. Calcd for C9H8O5: m/z 196.04 
(Figure 1). Anal. Found: C, 55.12; H, 4.02. Calcd for: 
C, 55.11; H, 4.11%. 
Ethyl haematommate, 5: Greenish solid. Mol. 
Formula: C11H12O5. Yield: 15 mg. Rf: 0.6 (DCM: 
Ethyl acetate, 7:3); m.p.112-113°C. UV (Ethanol) λmax 
(log ɛ) 209.5 nm; 1H NMR (DMSO-d6, 400 MHz): δ 
0.93-0.97 (3H, t, J= 8 Hz, 9-CH3), 1.59-1.65 (2H, m, 
8-CH2), 2.54 (3H, s, 11-CH3), 6.42 (1H, s, 5-ArH), 
9.68 (1H, s, 4-OH), 10.59 (1H, s, 2-OH), 13.75 (1H, s, 
10-CHO); 13C NMR (DMSO-d6, 400 MHz): δ 14.28 
(C-11), 20.14 (C-9), 68.63 (C-8), 105.25 (C-1), 
109.34 (C-5), 114.78 (C-3), 155.22 (C-6), 163.90 (C-
4), 167.04 (C-2), 173.42 (C-7), 191.73 (C-8); ESI-MS 
[M-H]+: m/z 224.9. Calcd for C11H12O5: m/z 224.07 
(Figure 1). Anal. Found: C, 58.64; H, 5.52. Calcd for: 
C, 58.93; H, 5.39%. 
Atranorin, 6 3: Colorless crystals. Mol. Formula: 
C19H18O8. Yield: 90 mg. Rf: 0.4 (DCM:Ethyl acetate, 
1:1) (Figure 1). 
 
Antioxidant activity 
In general, natural antioxidants maintain high 
tolerance to humankind without considerable side 
effects. The anti-radical assays of all the samples (1-6 
and Pt-Et) against DPPH and superoxide radicals 
were illustrated in Table SI and Table SII, 
respectively. The inferior IC50 values indicate higher 
inhibition of free radicals. From the antioxidant 
results, it is confirmed that the Pt-Et displayed to 
have promising anti-radical scavenging capacities. In 
both the antioxidant assays, the 1-6 and Pt-Et showed 
markedly higher radical scavenging activity.  
In DPPH radical scavenging assay, the antioxidant 
substances can reduce the stable purple-colored 
DPPH radical to a yellow-colored non-radical DPPH-
H form. In general, the DPPH radical quenching 
activity of antioxidants are assigned to their hydrogen 
(donating) capacities9,12,13. As shown in the Figure 2, 
the IC50 values remained 56.25, 60.0, 40.0, 53.0, 50.5 
and 53.5, µg/mL for 1, 2, 3, 4, 5 and 6, respectively, 
while standard ascorbic acid continued to exist at  
27.0 µg/mL. In addition to that, the IC50 values for Pt-
Et remained 95.0 µg/mL. 
The superoxide radical generally shows up from 
metabolic process/ROS, which interacts with other 
substrates in the presence of enzyme/metal-catalyzed 
processes to generate hydroxyl radicals, H2O2, and 
1O2. These radicals persuade oxidative damage in 
DNA, lipids, and proteins9,12,13. In the case of 
superoxide radical-quenching assay of all the samples 
(1-6 and Pt-Et) were tabulated in Table SII. From 
Figure 2, it was interesting to note that compound 3 
showed pronounced inhibition of superoxide free 
radicals with an IC50 value of 26.0 µg/mL than 
standard (35.5 µg/mL). Compounds 4 and 5 revealed 
almost equivalent inhibition of superoxide free radical 
to that of the standard drug ascorbic acid with IC50 
valuing of about 37.25 and 36.0 µg/mL, respectively. 
The concentration of 1, 2, 6, and Pt-Et, which needed 
50% inhibition of superoxide radicals, was  
found to be 62.5, 80.0, 48.0, and 99.75 µg/mL. Based 
on the aforementioned factors, it can be concluded 
that P. tinctorum has an aptitude to act against free 
radicals. 
 
Figure 2 — IC50 values of 1-6 and Pt-Et against free radicals and 
tested cancer cell lines 





The cytotoxicity studies of ethanolic extract of  
P. tinctorum (Pt-Et) and its isolates (1-6) were screened 
against six different human cancer cell lines (MDA-
MB-231, SW620, HeLa, FADU, A549, SKOV3) by 
SRB colorimetric assay10,11 using doxorubicin as 
standard. The results of percentage growth inhibition 
were illustrated in Table SIII. Concurrently, the 
toxicity studies of all the samples (1-6 and Pt-Et) 
were tested on normal human cell lines such as 
NHME. 
Initially, extracts Pt-Et (at 100 µg/mL 
concentration), isolated metabolites 1-6 (at 30 µg/mL 
concentration) and doxorubicin (at 10 µg/mL 
concentration) were screened against selected panel of 
cancer cell lines. The results were tabulated in Table 
SIII. During the initial screening, 4, 5, and Pt-Et 
showed a prominent degree of specificity against 
HeLa, FADU, and A549 moderate degree of 
specificity against MDA-MB-231, SW620, and 
SKOV3. Also, compound 1 showed a significant 
degree of specificity against SW620. In addition to 
that, all the samples exhibited a shallow degree of 
specificity against NHME cell lines, indicating that 
they are non-toxic against normal human cells (Table 
SIII). From Table SIII, it is compelling to notice that 
the Pt-Et (100 µg/mL concentration), as well as, the 
compounds 1 (30 µg/mL concentration) showed more 
pronounced growth by inhibiting profile against  
the SW620 than that of the doxorubicin (10 µg/mL 
concentration). Particularly, Pt-Et (100 µg/mL 
concentration) showed more pronounced growth by 
inhibiting profile against the A549 than that of the 
doxorubicin (10 µg/mL concentration). 
The active samples, i.e., which remain more than 
50% cell death were further screened at 25, 50, 75 and 
100 µg/mL concentrations to extract (Pt-Et); 5, 10,  
20 and 30 µg/mL concentrations as for pure 
compounds (1, 4 and 5); 2.5, 5.0, 7.5 and 10 µg/mL 
concentrations for standard (doxorubicin). The 
obtained results of percentage growth inhibition is 
plotted against concentrations to obtain IC50 values. 
The lower IC50 value indicates a better inhibitory 
profile against cancer cell lines. From Table SIV and 
Figure S16, it is evident that the Pt-Et showed a 
significant growth inhibitory profile against SW620 
with an IC50 value of 61.0 µg/mL (Figure 2). Among 
the isolates of Pt-Et, compound 1 showed better IC50 
values on SW620 with 26.5 µg/mL, while 
doxorubicin showed with 5.40 µg/mL (Figure 2). 
From the outcomes of the SRB assay of HeLa, it is 
concluded that Pt-Et displayed a reasonable cell death 
rate of HeLa with an IC50 value of 74.5 µg/mL and, 
the metabolites 4 and 5 showed a reasonable degree of 
specificity against HeLa when compared to 
doxorubicin. The concentration needed for 4 and 5 for 
50% growth inhibition of HeLa was found to be 27.0 
and 26.5 µg/mL, respectively, while doxorubicin to be  
4.5 µg/mL (Table SV, Figure S17, and Figure 2).  
Also, based on the cytotoxicity results of FADU, it is 
observed that Pt-Et revealed a significant degree of 
specificity against FADU with an IC50 value of  
62.5 µg/mL (Figure 2). The IC50 value of 4 and 5  
on FADU was found to be 20.0 and 25.5 µg/mL, 
respectively, while doxorubicin to be 3.8 µg/mL 
(Table SVI, Figure S18 and Figure 2). 
From Table SVII and Figure S19, it is evident that 
the Pt-Et showed a significant growth inhibitory 
profile against A549 with an IC50 value of 64.9 
µg/mL (Figure 2). Among the isolates of Pt-Et, 
compounds 4 and 5 showed better IC50 values on 
A549 with 22.5 and 27.5 µg/mL, respectively, while 
doxorubicin showed with 6.3 µg/mL (Figure 2). 
Additionally, from the SRB assay results, it can be 
concluded that the anticancer capabilities of Pt-Et 
were mainly due to the presence of compounds 1, 4, 
and 5. Also, compounds 4 and 5 showed better cancer 
cell lysis is due to the presence of higher levels of free 
oxygenated substituents in their chemical structure. 
Based on the outcomes, it can be concluded that  




To wind up, six known metabolites namely methyl-
β-orcinolcarboxylate (1), isolecanoric acid (2), 
methyl-2,6-dihydroxy-4-methylbenzoate (3), 
haematommic acid (4), Ethyl haematommate (5) and 
atranorin (6) were isolated from the ethanolic extract 
of manglicolous lichen P. tinctorum (Pt-Et), which 
were for the first time reported from P. tinctorum. 
From the pharmacological screening of the isolates 
(1-6), it was found that 3, 4, and 5 exhibited better 
inhibition of superoxide free radicals with an IC50 
value of 26.0, 37.25, and 36.0 mg/mL, respectively. 
Correspondingly, these compounds (4 and 5) revealed 
a remarkable degree of specificity towards HeLa, 
FADU and A549 and delicate degree of specificity 
towards a normal human cell line, in which, it justifies 
the compounds containing the antioxidant properties 
have an aptitude to treat cancer. Hence, this study 




represents the natural product researchers for  
further chemical and biological investigations of 








The authors thank the heads of AU College  
of Pharmaceutical Sciences, Andhra University, 
Visakhapatnam for providing the necessary facilities. 
No conflict of interest between any of the authors. 
 
References 
1 Nayaka S, Ingle K K, Bajpai R, Rawal J R, Upreti D K & 
Trivedi S, Current Research in Environmental Applied 
Mycology, 3(2) (2013) 222. 
2 Tatipamula V B, Vedula G S & Murthy K S, Studies in 
Fungi, 3(1) (2018) 302. 
3 Tatipamula V B, Vedula G S, Rathod B B, Shetty P R & 
Sastry A V S, Inventi Rapid: Planta Activa, 2018(3) (2018) 
129. 
4 Kumar J, Dhar P, Tayade A B, Gupta D, Chaurasia O P, 
Upreti D K, Arora R & Srivastava R B, PLoS One, 9(6) 
(2014) e98696. 
5 Logesh A R, Kalaiselvam M, Upreti D K, Nayaka S & 
Karthiresan K, Cocasal Ecosystems of India – Special 
Publication, 39 (2013). 
6 Raj P S, Prathapan A, Sebastian J, Antony A K, Riya M P, 
Rani M R, Biju H, Priya S & Raghu K G, Nat Prod Res, 
28(18) (2014) 1480. 
7 Talluri M R, Ketha A, Battu G R, Tadi R S & Tatipamula V B, 
Bangladesh J Pharmacol, 13(3) (2018) 287. 
8 Tatipamula V B, Vedula G S, Paidi K R & Annam S S P, 
Inventi Impact: Nutraceuticals, 2018(3) (2018) 189. 
9 Tatipamula V B, Vedula G S & Sastry A V S, Asian J Chem, 
31(4) (2019) 805. 
10 Tatipamula V B & Vedula G S, Hygeia J D Med, 10(1) 
(2018) 16. 
11 Vichai V & Kirtikara K, Nat Protoc, 1(3) (2006) 1112. 
12 Sastry A V S, Vedula G S & Tatipamula V B, Inventi 
Impact: Ethnopharmacology, 2018(3) (2018) 153. 
13 Tatipamula V B, Kolli M K, Lagu S B, Paidi K R, Reddy P R 
& Yejella R P, Pharmacol Rep 71(2) (2019) 233. 
 
